APD811-301 Phase 3 studies evaluating the efficacy and safety of ralinepag in patients with WHO Group 1 pulmonary arterial hypertension (PAH)

Brief description of study

The purpose of this research study is to assess an investigational medication called ralinepag (also referred to as the “investigational study drug”) in the treatment of pulmonary arterial hypertension (PAH). Ralinepag has not been approved by any regulatory authorities, including the US Food and Drug Administration (FDA); therefore, it is not available by prescription.

Clinical Study Identifier: s18-00438

ClinicalTrials.gov Identifier: NCT03626688

Principal Investigator: Roxana Sulica.

Other Investigators: Rebecca A Fenton, Frank E Cefali.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies